Axogen Stock Soars on FDA Approval for Nerve Repair Treatment
Axogen shares jumped 7% in premarket trading after FDA approved its Avance nerve repair treatment for adults and children, strengthening its market position.
NOTRELOAD AI
JPMorgan Downgrades Lennar Amid 2026 Housing Weakness
JPMorgan downgraded Lennar to Underweight with a reduced price target of $115, citing weak demand, supply challenges, and downside risk for homebuilders in 2026.
Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
JPMorgan Turns Bullish on Toast: Analyst Sees Big Upside Ahead
JPMorgan upgrades Toast to Overweight, keeping a $43 price target. The firm highlights strong growth, rising estimates, and potential upside if interchange fees face regulation.
Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.
UiPath Swings to Profit as AI Automation Demand Surges
UiPath reports Q3 profit with 16% revenue growth to $411M, driven by healthcare and financial services adopting AI automation. ARR grows 11% to $1.78B.